Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic
about
Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury.Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers.Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models.Cellular processes associated with LRRK2 function and dysfunctionBasic science breaks through: New therapeutic advances in Parkinson's disease.How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study.Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease.Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.LRRK2 dephosphorylation increases its ubiquitination.Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.Progression in the LRRK2-Asssociated Parkinson Disease Population.LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network.Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.Mechanisms of Mutant LRRK2 Neurodegeneration.LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.Parkinson disease: Insect screens for PD therapies - keep the flies in.
P2860
Q35766417-EB94BB8C-1A80-4BE2-A721-ED2E731E88EFQ35925767-91074018-F13F-4F87-BCA8-E32D590FD556Q36706040-098647F5-AE9B-446C-8DAC-054C020A5A1BQ38270479-124A1939-37E8-4013-A00B-14A0306BADD8Q38433725-C411F086-62BB-410C-A776-A37507E2AE03Q38547662-5B89D763-A36A-44F8-8789-47DC4CAF4A19Q38790881-21FE89E4-DDA4-4D80-84AD-3CD83E58364CQ39149219-0F3CF5DF-5D8B-4B5D-BEC4-E3AB3E93D711Q39366467-63C796E3-8917-4EFD-82EF-248FE98C6C00Q39686532-74A5FDDA-E3A9-480F-96C9-7F94F3D0381BQ39967268-3FF47528-1426-4496-976D-004E78719B01Q41374126-9435BFA9-099F-402A-A62D-7035F4E407B7Q41785779-8734E486-6A6B-43D7-AC7C-01964B3D4569Q42372493-95DEC801-0E1E-469E-8E6C-192CE8457014Q47198236-9BE1EB1C-F73D-4EA7-942D-C7D1CC85A014Q47362838-B67DBFF1-9E52-4F75-A882-618A41D3F53EQ48003270-F75795E3-0B9E-47EA-ACCB-2E58ACC44755Q48239635-63FD85CE-2D56-4D29-B2DD-01142762BDB1Q48560989-F4624BFB-189D-4980-88A3-D63F761EC1BAQ52847929-EBB3FFFA-ED38-4F70-BCEA-19A8B3238423
P2860
Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic
@ast
Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic
@en
Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic
@nl
type
label
Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic
@ast
Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic
@en
Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic
@nl
altLabel
Ten Years and Counting: Moving Leucine-Rich RepeatKinase 2 Inhibitors to the Clinic
@en
prefLabel
Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic
@ast
Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic
@en
Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic
@nl
P2860
P921
P3181
P356
P1433
P1476
Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic
@en
P2093
Andrew B. West
P2860
P304
P3181
P356
10.1002/MDS.26075
P407
P5008
P577
2014-12-01T00:00:00Z